Electrical Cell-substrate Impedance Sensor (ECIS)

ABSTRACT

A method for detection and monitoring a therapeutic effect of a cancer treatment drug is disclosed. The method includes steps of removing a malignant biological cell lines from a tumor; culturing the removed biological cell lines in a controlled set of conditions; seeding the cultured biological cell lines on silicon nanowire electrode arrays of an electrical cell-substrate impedance sensor (ECIS); adding a cancer treatment drug to the seeded biological cell lines to treat the seeded biological cell lines; and measuring an electrical impedance of the treated biological cell lines for detection and monitoring a therapeutic effect of the cancer treatment drug.

CROSS REFERENCE TO RELATED APPLICATION

The present application claims priority from pending U.S. ProvisionalPatent Application Ser. No. 62/127,803, filed Mar. 3, 2015, entitled “ABiosensor for Monitoring the Spreading Stage of the Cells andApplications thereof for Cancer Diagnosis”, which is incorporated byreference herein in its entirety.

TECHNICAL FIELD

The present application generally relates to a device including asilicon nanowire based electrical cell impedance sensor (designatedhereinafter as “SiNW-ECIS”) and a method for fabrication of a SiNW-ECIS.Moreover, the use of a SiNW-ECIS as a biosensor for detecting theelectrical response of cultured living cells, specifically cancerouscells is disclosed.

BACKGROUND

The cancer cells are different from healthy cells in reproduction,adhesion, proliferation rate, maturation and function (specialization),which all might affect the electrical and chemical signals recorded fromthe cell. Biologists introduce the cancer as a disease, characterized bythe autonomous aimless and excessive proliferation of cells.

The growing cycle of the biological cells includes three main phases.The three main phases include (i) attachment to a substrate, (ii)spreading or stretching of cell until splitting, and (iii) proliferationor mitosis. The spreading stage, as one of the importantpre-proliferation stages, may contain many distinguishable parametersbetween normal and malignant cells. In addition, the effect ofanti-cancer drugs may be distinguishable at the spreading stage. Thespreading stage may occur about 10 hours before the proliferation stage.Therefore, it may be advantageous to determine the cancerous state ofthe cell during the spreading stage and also determine the anti-cancerdrug effects during the spreading stage. However, the impedimetricmonitoring of the spreading stage in normal and cancerous cells has notbeen carried out for diagnosis applications to date.

Hence, there is a need for fabrication of cancer cells ECIS biosensorswith the ability to diagnose the cancer cells at their spreading stagefor a faster response.

SUMMARY

In one general aspect of the present application, an electrical cellsubstrate impedance sensor (ECIS) for measuring an electrical responseof a biological cell is disclosed. The ECIS includes a substrate, acatalyst layer formed on the substrate; and a plurality of nanowireelectrodes array grown on the catalyst layer, the plurality of nanowireelectrodes are configured to measure an electrical response of abiological cell.

The above general aspect may include one or more of the followingfeatures. The substrate may include a silicon dioxide (SiO₂) layer grownon a silicon chip or a silicon wafer. The catalyst layer may include ananometer sized layer of gold or a bilayer of Ni—Au. The nanowireelectrodes may include a plurality of silicon nanowires (SiNWs) having athickness less than 100 nanometers.

In another general aspect of the present application, a method forfabricating a silicon nanowire based electrical cell substrate impedancesensor (SiNW-ECIS) is described. The method includes the steps of:growing a layer of silicon dioxide (SiO2) on a silicon chip or a siliconwafer, as the substrate layer, using a wet oxidation furnace or chamber;forming a catalyst layer on the substrate layer via a sputteringtechnique; etching the catalyst layer in a region corresponding to thesensor region on the substrate through a photolithography process;growing a plurality of silicon nanowire (SiNW) arrays configured tomeasure an electrical response of a biological cell on the sensor regionto form a SiNW-ECIS; and transferring the SiNW-ECIS into a dopingfurnace

The above general method aspect may include one or more of the followingfeatures. The doping furnace may include a phosphorous doping furnace toenhance the electrical conductivity of nanowires. Furthermore, a devicefor measuring the electrical response or impedance of a biological cellline may be presented in the present application. The device may includea sensor package including SiNW-ECIS, a system for applying andacquiring the electrical signals and data to the biological cell linesattached on the ECIS silicon nanowires placed within the sensor package,and a data processor to record and process the acquired data.

In another general aspect of the present application, a method fordetecting and monitoring the spreading stage of a biological cell forcancer diagnosis is disclosed. The method includes steps of: removingbiological cell lines from a normal tissue or a cancerous tumor;culturing the removed biological cell lines via maintaining in acontrolled set of conditions; seeding the cultured biological cellslines on silicon nanowire electrode arrays of a SiNW-ECIS describedabove; and measuring an electrical impedance of the seeded biologicalcell lines to detect and monitor a spreading state of the seededbiological cell lines for cancer diagnosis.

In another general aspect of the present application, a method fordetecting and monitoring the therapeutic effects of specific cancertreatment drugs is disclosed. The electrical response of the cancerouscells treated by low concentrations of specific drugs, particularly,antitubulin drugs is recorded after short time intervals of drugincubation. The method is carried out using the SiNW-ECIS and themeasuring device including the SiNW-ECIS, designed and fabricatedpursuant to the teachings of the present application.

In one implementation, the method for detecting and monitoring thetherapeutic effects of cancer treatment drugs includes the steps of:removing a malignant biological cell lines from a tumor; culturing theremoved biological cell lines in a controlled set of conditions; seedingthe cultured biological cell lines on silicon nanowire electrode arraysof an electrical cell-substrate impedance sensor (ECIS); adding atreatment drug to the seeded biological cell lines to treat the seededbiological cell lines; and measuring an electrical impedance of thetreated biological cell lines for detection and monitoring thetherapeutic effect of a specific cancer treatment drug, particularly,antitubulin drugs.

In another implementation, cell lines culturing in both methodsmentioned hereinabove for cancer diagnosis and monitoring thetherapeutic effects of cancer drugs may be achieved by maintaining thecell lines in a controlled set of conditions including maintaining thecell lines in a medium, particularly, RPMI-1640 medium and in a CO₂incubator at a specific temperature.

In another implementation, seeding the cultured biological cell lines inboth methods mentioned hereinabove for cancer diagnosis and monitoringthe therapeutic effects of cancer drugs may include: dropping thecultured biological cell lines on a surface of a packed and sealed ECIS;and maintaining the dropped biological cell lines in an incubator toachieve attachment between the biological cell lines and the siliconnanowire electrode arrays of ECIS. The treatment drug addition mayinclude: first, adding a specific amount of the treatment drug on asurface of the biological cell lines attached on the silicon nanowireelectrode arrays, and second, maintaining the biological cell lines withthe added treatment drug in an incubator for a specific time interval.

Furthermore, measuring the electrical impedance in both methodsmentioned hereinabove for cancer diagnosis and monitoring thetherapeutic effects of cancer drugs may include measuring the electricalimpedance via the device disclosed in the present application including:applying a specific voltage of about 400 mV to the sensor package havingthe biological cells attached to the silicon nanowire electrode arrays,and measuring the electrical impedance of the biological cells attachedto the silicon nanowire electrode arrays at various specific frequenciesin a range of about 100 Hz to 150 KHz.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A illustrates a schematic of an exemplary SiNW-ECIS fabricatedpursuant to the teachings of the present application;

FIG. 1B illustrates a schematic of a plurality of silicon nanowiresgrown on the sensor region pursuant to the teachings of the presentapplication;

FIG. 2 illustrates an exemplary fabrication method for a SiNW-ECISdevice, pursuant to the teachings of the present application;

FIG. 3 illustrates a schematic of the device designed for impedancemeasurements including a sensor package, a system for electrical signalapplication and data acquisition, and a data processor;

FIG. 4 illustrates an exemplary method for detecting and monitoring thespreading stage of a biological cell using the SiNW-ECIS device shown inFIG. 3;

FIG. 5 illustrates an exemplary process for detecting and monitoring thetherapeutic effect of specific cancer treatment drugs using theSiNW-ECIS device shown in FIG. 3;

FIG. 6A illustrates an exemplary scanning electron microscope (SEM)image of SiNW-ECIS prepared pursuant to the teachings of the presentdisclosure, showing the geometry and architecture of SiNW-ECIS with areference scale of 333 μm;

FIG. 6B illustrates an exemplary SEM image of SiNW-ECIS preparedpursuant to the teachings of the present disclosure, showing thegeometry and architecture of SiNW-ECIS with a reference scale of 60.0μm;

FIG. 6C illustrates an exemplary SEM image of SiNW-ECIS preparedpursuant to the teachings of the present disclosure, showing thegeometry and architecture of SiNW-ECIS with a reference scale of 5.00μm;

FIG. 7 illustrates an exemplary SEM image of SiNW-ECIS prepared pursuantto the teachings of the present application, showing the geometry andarchitecture of SiNWs after the cells interactions and attachment withthe silicon nanowires;

FIG. 8A illustrates MTT(3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assayresults of a sample of lung tumor cells (QU-DB cell lines) seeded onSiNW-ECIS with doped and un-doped silicon nanowires;

FIG. 8B illustrates Florescent images of QU-DB cells seeded on SiNW-ECISbefore proliferation stage;

FIG. 8C illustrates Florescent images of QU-DB cells seeded on SiNW-ECISafter proliferation stage;

FIG. 9A illustrates comparative impedance values recorded by theSiNW-ECIS device covered by QU-DB cell lines during different culturingstages: initial drop-attachment (top left); attachment-spreading (topright); spreading-proliferation (bottom);

FIG. 9B illustrates comparative impedance values recorded by theSiNW-ECIS device covered by MRC-5 cell lines during different culturingstages: initial drop-attachment (top left), attachment-spreading (topright); and spreading (bottom);

FIG. 10A illustrates a field emission electron microscope (FESEM) imageof a single QU-DB cell seeded on SiNW-ECIS at an initial drop stage;

FIG. 10B illustrates a FESEM image of a single QU-DB cell cultured onSiNW-ECIS at an attachment stage;

FIG. 10C illustrates a FESEM image of a single QU-DB cell cultured onSiNW-ECIS at a spreading stage;

FIG. 10D illustrates a FESEM image of a single QU-DB cell cultured onSiNW-ECIS at a proliferation or a mitosis stage;

FIG. 10E illustrates a FESEM image of a single MRC-5 cell cultured onSiNW-ECIS at an attachment stage;

FIG. 10F illustrates a FESEM image of a single MRC-5 cell cultured onSiNW-ECIS at a spreading stage;

FIG. 10G illustrates a FESEM image of a single MRC-5 cell cultured onSiNW-ECIS at a continued spreading stage;

FIG. 11A illustrates the impedance phase diagram of malignant lung cell(QU-DB) cultured on SiNW-ECIS reported from five individual tests atdifferent frequencies for an initial dropping (designated by the symbol♦) and cells attachment (designated by the symbol ▪) after 3.5 hours;

FIG. 11B illustrates the impedance phase diagram of QU-DB cultured onSiNW-ECIS reported from five individual tests at different frequenciesfor cells attachment (designated by the symbol ▪) after 3.5 hours and aspreading stage (designated by the symbol ▴) after 6.5 hours;

FIG. 11C illustrates the impedance phase diagram of normal lung cell(MRC-5) cultured on SiNW-ECIS reported from five individual tests atdifferent frequencies for an initial dropping (designated by the symbol♦) and cells attachment (designated by the symbol ▪) after 3.5 hours;

FIG. 11D illustrates the impedance phase diagram of MRC-5 cultured onSiNW-ECIS reported from five individual tests at different frequenciesfor cells attachment (designated by the symbol ▪) after 3.5 hours and aspreading stage (designated by the symbol ▴) after 6.5 hours;

FIG. 12A illustrates the normalized diagram of impedance and capacitancechanges for MCF-7 cells seeded on SiNW nano electrodes 2 hours (T1)after treating by 2.1 nano-moles per liter of Albendazole (ABZ) versusthe control sample;

FIG. 12B illustrates the normalized diagram of impedance and capacitancechanges for MCF-7 cells seeded on SiNW nano electrodes 2 hours (T1)after treating by 0.1 nano-moles per liter of Paclitaxel (PTX) versusthe control sample;

FIG. 12C illustrates the normalized diagram of impedance and capacitancechanges for MCF-7 cells seeded on SiNW nano electrodes 6 hours (T2)after treating by 2.1 nano-moles per liter of ABZ versus the controlsample;

FIG. 12D illustrates the normalized diagram of impedance and capacitancechanges for MCF-7 cells seeded on SiNW nano electrodes 6 hours (T2)after treating by 0.1 nano-moles per liter of PTX versus the controlsample;

FIG. 12E illustrates the normalized diagram of impedance and capacitancedifferences for control (untreated) MCF-7 cells seeded on SiNWelectrodes between 2 hours (T1) and 6 hours (T2) incubation periods;

FIG. 12F illustrates the normalized diagram of impedance and capacitancedifferences for control (untreated) MCF-7 cells seeded on SiNWelectrodes between 2 hours (T1) and 6 hours (T2) after treating by 2.1nano-moles per liter of ABZ;

FIG. 12G illustrates the normalized diagram of impedance and capacitancedifferences for control (untreated) MCF-7 cells seeded on SiNWelectrodes between 2 hours (T1) and 6 hours (T2) after treating by 0.1nano-moles per liter of PTX;

FIG. 13A illustrates a confocal microscopy image from the tubulinassemblies of MCF-7 cells after 2 hours incubation, named as controlsample;

FIG. 13B illustrates a confocal microscopy image from the tubulinassemblies of MCF-7 cells treated with 2.1 nano-moles per liter ABZafter 2 hours incubation;

FIG. 13C illustrates a confocal microscopy image from the tubulinassemblies of MCF-7 cells treated with 0.1 nano-moles per liter PTXafter 2 hours incubation;

FIG. 14A illustrates a confocal microscopy image from the tubulinassemblies of MCF-7 cells after 6 hours incubation, named as controlsample;

FIG. 14B illustrates a confocal microscopy image from the tubulinassemblies of MCF-7 cells treated with 2.1 nano-moles per liter ABZafter 6 hours incubation; and

FIG. 14C illustrates a confocal microscopy image from the tubulinassemblies of MCF-7 cells treated with 0.1 nano-moles per liter PTXafter 6 hours incubation.

DETAILED DESCRIPTION

The following detailed description is presented to enable a personskilled in the art to make and use the application. For purposes ofexplanation, specific nomenclature is set forth to provide a thoroughunderstanding of the present application. However, it will be apparentto one skilled in the art that these specific details are not requiredto practice the teachings of the present application. Descriptions ofspecific applications are provided only as representative examples.Various modifications to the implementations discussed in the presentapplication will be readily apparent to one skilled in the art, and thegeneral principles defined herein may be applied to otherimplementations and applications without departing from the scope of thepresent application. The present application is not intended to belimited to the implementations shown, but is to be accorded the widestpossible scope consistent with the principles and features disclosedherein.

Nanostructured materials, as nanoscale interactors, have suitablebioelectrical properties, leading to a development of a new generationof nanostructured-based ECIS. Electrically active nanomaterials couldhave well-directed electrical interaction with cell outer-wall topenetrate the electric field into the cell membrane for signal recordingpurposes. Among various nanomaterials applied in bio-sensing processes,silicon nanowires (SiNWs) have found a wide range of applications in thefield of bioelectronics. This is because SiNWs have unique chemical andphysical properties and may be compatible with the fabrication processof electronic devices.

To this end, the present application describes a device including asilicon nanowire-based electrical cell impedance sensor (SiNW-ECIS) andthe fabrication method thereof. The SiNW-ECIS may have a simplefabrication and testing process and may be considered for label-freecancer detection methods, especially when large amount of cells arerequired to be checked.

The SiNW-ECIS is a biosensor that monitors the spreading stage ofbiological cells. The spreading stage may include a stage at which thebiological cells stretch and become extended on the nanowires surface.The SiNW-ECIS is configured to detect the cancerous state of culturedliving cells by monitoring the spreading stage of the biological cells.Additionally, the SiNW-ECIS is configured to investigate the effect ofanti-cancer drugs via monitoring their interruption effects on thepolymerization/depolymerization of microtubules (MTs) in the cellstructure, during spreading and proliferation stages in a cell cycle.

The direct interaction between the SiNWs and the cell membrane canenhance the accuracy and the state of the resultant electrical responseof biological cells. The nanowires act as both an adhesive layer (forcell attachment) and a conductive layer (to extract electrical signalfrom the cells). Accordingly, there is no need for an excess layer of anadhesive material, which is required in the case of titanium-gold(Ti—Au)-nanowires coated ESIC. In addition, the great biocompatibilityof SiNW-ECIS produced as disclosed in the present application, makes ita suitable electrical biosensor with the capability of sensing the slimvariations in dielectric constants of seeded cells during their membraneextension in the spreading state.

On the other hand, the spreading stage as one of the importantpre-proliferation steps or stages (occurring about 10 hours beforeproliferation stage) would contain many distinguishable parametersbetween normal and malignant cells. However, as noted above, theimpedimetric monitoring of the spreading stage in normal and cancerouscells has not been carried out for diagnosis applications to date.Hence, fabrication of cancer cells ECIS biosensors with the ability todiagnose the cancer cells at their spreading stage could lead to muchfaster responses and be a helpful alternative for common electricalimpedance sensors.

In one implementation, the presented SiNW-ECIS biosensor has athree-layered structure, including: a substrate, a thin catalyst layerformed on the substrate; and a plurality of nanowire electrodes arraycoated on the catalyst layer. The substrate may be a silicon chip orwafer coated by a layer of silicone dioxide (SiO₂). The substrate mayhave a thickness of about 1 cm or less. The catalyst layer may be madeof gold or a bilayer of Ni—Au with a thickness of about 10 nm or less.The plurality of nanowires may include SiNWs grown on a specificpatterned zone of the catalyst layer. The SiNWs may have a thickness ordiameter in a range of 50 nm to about 90 nm or less.

FIG. 1A illustrates a schematic structure of a SiNW-ECIS device 100. TheSiNW-ECIS device 100 includes a silicon chip or a silicon wafer 101; aSiO₂ layer 102 grown on the silicon chip or silicon wafer 101; and acatalyst layer 103 deposited on the silicon oxide layer 102 andpartially patterned in an arbitrary designed region (designatedhereinafter as “sensor region”). The sensor region may be considered forgrowth of nanowires electrode. As shown, the SiNW-ECIS device 100 alsoincludes a plurality of nanowire arrays 104 grown on the patternedcatalyst layer 103 in the sensor region. FIG. 1B illustrates the grownSiNWs 104 on the patterned catalyst layer 103.

The SiNW-ECIS device 100 can be fabricated via a method including stepsof: first, growing a layer of silicon dioxide (SiO₂) 102 on a siliconchip or wafer 101 as a substrate layer; second, coating or depositing acatalyst layer 103 on the grown silicon oxide layer 102; third,patterning and etching the catalyst layer 103 in a region considered asthe sensor region transferred on the substrate 101; fourth, growing aplurality of SiNW arrays 104 on the sensor region; and fifth,transferring the prepared SiNW-ECIS device 100 into a doping furnace.

FIG. 2 shows an exemplary process for fabricating the SiNW-ECIS device100. Referring also to FIG. 1A, in the first step 201, a layer ofsilicon dioxide is grown on an initially supplied silicon chip or wafer101, for example via a wet oxidation furnace or chamber at a temperatureof about 1050° C. The silicon oxide 102 may have a thickness of about250 nm on the silicon chip or wafer 101 having a thickness of about 1 cmor less.

The second step 202 involves coating or depositing a catalyst layer 103over the silicon oxide layer 102, using, for example, a sputteringsystem. The catalyst material can be for example gold or a bilayer ofNi—Au, which is deposited or coated with a thickness of about 10 nm.

The third step 203 involves patterning and etching the catalyst layer103, which may be carried out through a photolithography process.Accordingly, the catalyst layer 103 partially is patterned in aconsidered region for growing sensor electrodes which is named as thesensor region.

The fourth step 204 involves growing a plurality of SiNWs 104, as thesensor electrodes array on the patterned sensor region over the catalystlayer 103. The SiNWs 104 may be grown via a vapor-solid-liquid (VLS)process using a low-pressure chemical vapor deposition (LPCVD) system.The VLS process may be carried out by the assistance of H₂ and SiH₄gases at a temperature of about 450° C.

The fifth or final step 205 involves transferring the as-preparedSiNW-ECIS device 100 into a doping furnace to enhance the conductivityof SiNWs 104. The doping step can be carried out by an element of groupfive of the periodic table, for example, using a phosphorous dopingfurnace.

It should be understood that the SiNW-ECISs, designed and fabricatedpursuant to the teachings of the present application, may bebiocompatible in interaction with a wide range of biological cells. Forexample, the SiNW-ECISs may be biocompatible with epithelial cells,breast cells, etc.

In another aspect of the present application, a measuring deviceincluding the SiNW-ECIS is designed for measuring and recording theelectrical response or impedance of a biological cell line.

FIG. 3 illustrates a schematic of the measuring device 300 designed forelectrical impedance measurements of cells. The device 300 includes asensor package 301, a system for electrical signal application by an ACsignal source 302, a data acquisition module 303, and a data processor304.

The sensor package 301 includes a SiNW-ECIS device (e.g., the SiNW-ECISdevice 100) designed and fabricated pursuant to the teachings of thepresent application, which can be packed, for example in a glass coverand can be sealed with, for example a biograde silicon rubber tube. Theglass may be Plexiglas. The AC signal source 302 and the dataacquisition module 303 can be fabricated based on an IC: AD 5933 in anindividual board. The AC signal source 302 may be configured to applydifferent voltages at different frequencies on the sensor package 301.The data acquisition module 303 may be configured to acquire thecorresponding resultant electrical responses. The applied voltage canbe, for example about 400 mV and the applied frequencies can be, forexample, in the range of about 100 Hz to 150 KHz. The data processor 304may receive the data from data acquisition module 303, record, and drawcorresponding curves for further data analysis.

In another aspect of the present application, a method is described fordetecting and monitoring the spreading stage of a biological cell viameasuring electrical cell impedance using a SiNW-ECIS device. Thismethod may be used for cancer diagnosis, cancerous tumors growthmonitoring at metastatic stage, or generally for cancerous statedetermination of malignant tissues or cells at early stages of cancerprogression.

In one implementation, the method for detecting and monitoring thespreading stage of a biological cell includes four main steps of: first,removing and isolating a biological cell line, second, culturing andpreparing the cell lines in an appropriate controlled set of conditions,third, seeding the prepared cell lines on the electrode arrays of anECIS; and fourth, measuring and recording the electrical impedance ofthe ECIS covered by the cell lines at specific frequencies.

FIG. 4 shows an exemplary method 400 for detecting and monitoring thespreading stage of a biological cell pursuant to the teachings of thepresent application. In the first step 401, biological cell lines may beremoved and isolated from a normal tissue or malignant cancerous tumor.For example, the biological cell lines may be removed and isolated fromthe epithelial healthy tissues or tumors. More specifically, thebiological cell lines may be, for example, MRC-5 (Medical ResearchCouncil 5) cell lines isolated from normal healthy lung tissues or QU-DBcell lines isolated from malignant cancerous lung tissues.

In the second step 402, the isolated cell lines are cultured in anappropriate controlled set of conditions. The isolated cell lines may bemaintained in an appropriate medium, such as a Roswell Park MemorialInstitute-1640 (RPMI-1640) medium. The medium may be replaced with afresh medium every day before electrical impedance measurements. Also,the cell lines may be maintained in a CO₂ incubator containing CO₂ andclean air. The gas composition of incubator may be about 5% for CO₂ and95% for clean air.

In the third step 403, the isolated and cultured cell lines are seededon the ECIS surface. In one implementation, the ECIS can be a SiNW-ECIS.The third step 403 can include dropping the prepared cell lines on thesurface of a packed and sealed ECIS and maintaining the cell linesseeded on the ECIS in an incubator to achieve cell attachment on theSiNWs.

In one implementation, the isolated and cultured cell lines are droppedon the surface of the ECIS with a volume of, for example about 300 μl.Then, the ECIS is maintained in an incubator for complete attachment ofthe cells to the nanowires. The ECIS can, for example, be maintained inthe incubator for about 3 hours to 10 hours. The obtained SiNW-ECISsincluding the attached cells from the present step are named as“samples” considered for more investigations in the following steps.

The final step 404, involves measuring and recording the electricalimpedance of the samples, which is carried out using the measuringdevice 300 of FIG. 3. The measurement of electrical impedance of theprepared samples can include applying a specific voltage on the ECISpackage including the isolated and cultured cells attached to the SiNWelectrode arrays; and measuring and reading out the impedance of thesamples at various specific frequencies. The impedance measurements canbe carried out at frequencies in a range of, for example, about 100 Hzto about 150 KHz.

In another general aspect, a method for measuring and monitoring of thetherapeutic effect of anticancer drugs, particularly, antitubulin drugsis proposed in the present application. The method is based on theeffect of the polymerization/depolymerization process rate ofmicrotubules (MTs) on the bioelectrical properties of a cell membrane,particularly, the electrical impedance of biological cells.Additionally, the method reliability can be investigated by standardtests, such as Confocal, flowcytometry and tubulin assembly assays. Theresults from foregoing tests may be used to observe the mechanism inwhich antitubulin drugs cause electrical response variations of thecancerous cells due to their therapeutic effects throughpolymerization/depolymerization process rate variations of MTs in cellcytoskeleton.

It should be understood that MTs, as one of the key components incytoskeleton with crucial role in metabolisms and disease transformationof mammalian cells, interact extensively and intimately with cellularmembranes. The MTs make up the internal structure of cilia and flagella,which are covered by an extension of the plasma membrane. In addition,tubulin and membrane proteins are bound with each other by Ankyrins,including the cell-cell adhesion proteins, E-cadherin and the Na⁺/K⁺ATPase in epithelial cells. Ankyrin-G also binds Na⁺ channel andβ-subunits. MTs are also involved in exocytosis and endocytosisinitiated by the membrane. Hence, any disruption in MTs structure andfunction, such as polymerization or depolymerization rate variationscaused by antitubulin drugs can induce dramatic changes in the shape andfunction of the membrane. Therefore, these changes might rapidly affectthe electrical responses of the membrane, because biological functionsof the membrane affect their electrical activities. Accordingly, whenthe function and dielectric properties of the membrane is affected byMTs disruption, the current penetration into the membrane would bechanged significantly.

Accordingly, a method is described in the present application fordetection and monitoring the therapeutic effects of specific cancertreatment drugs via measuring electrical cell impedance of the membraneof target cells, using a device based on SiNW-ECIS. This method can beused for investigating and detecting the therapeutic effect of, forexample, antitubulin drugs in cancer treatments. Also, the method may beused for determining the dosage of antitubulin drugs in cancertreatments.

FIG. 5 illustrates an exemplary method 500 for detection and monitoringthe therapeutic effects of specific drugs using the measurement device300 shown in FIG. 3. The method 500 includes five main steps of:removing and isolating a malignant biological cell lines (step 501);culturing and preparing the cell lines in an appropriate controlled setof conditions (step 502); seeding the prepared cell lines on theelectrode arrays of an ECIS device (e.g., the SiNW-ECIS device 100)(step 503); treating the cell lines by adding a drug on the seeded celllines (step 504); and finally, measuring and recording the electricalimpedance of the ECIS device, which is covered by treated cell lines, atspecific frequencies (step 505).

In the first step 501, the biological cell lines may be removed andisolated from a malignant cancerous tumor. For example, the biologicalcell lines may be removed and isolated from a breast tumor. Thebiological cell lines may be the MCF-7 (Michigan Cancer Foundation-7)cell lines isolated from a breast tumor.

In the second step 502, the isolated biological cell lines are culturedin an appropriate controlled set of conditions. Accordingly, theisolated cell lines are maintained in an appropriate medium, such as aRoswell Park Memorial Institute-1640 (RPMI-1640) medium. The medium maybe replaced with a fresh medium every day before electrical impedancemeasurements. The isolated cell lines can be maintained in a CO₂incubator containing 5% CO₂ and 95% clean air, at a temperature of about37° C.

In the third step 503, the cultured cell lines are seeded on the ECISsurface. The ECIS may be the SiNW-ECIS device 100 shown in FIG. 1. Thethird step 503 involves dropping the cultured cell lines on the surfaceof the packed and sealed ECIS device and maintaining the packed andsealed ECIS device containing the dropped cell lines in an incubator toachieve cell attachment on the SiNWs. The cultured cell lines may bedropped on the surface of the packed and sealed ECIS device with avolume of, for example about 300 μl. Then, the packed and sealed ECISdevice can be maintained in an incubator for complete attachment of thecell lines to the nanowires. In one specific example, the packed andsealed ECIS device can be maintained in an incubator for about 3 hoursto about 10 hours. The obtained ECIS device including the attached celllines may be considered “samples” and used for more investigations inthe following steps.

In the fourth step 504, anti-cancer drugs with specific amounts areadded to the samples after cell attachment on the SiNWs for treatment ofthe cells. Then, the samples are maintained in an incubator for adesired time interval. The anti-cancer drugs can be, for exampleantitubulin drugs such as Albendazole (ABZ), Paclitaxel (PTX) or anyother antitubulin drug. The drug may have a concentration of, forexample about 0.1 to 20 nano-mole per liter. The treated samples can bemaintained in an incubator for at least about 2 hours before electricalassay.

In the final step 505 the electrical impedance of the treated cells ismeasured and recorded using the measuring device 300 shown in FIG. 3.The measurement of the electrical impedance of the treated cellsincludes applying a specific voltage on the ECIS package including thetreated cells attached to the SiNW electrode arrays and measuring andreading the impedance of the samples at various specific frequencies.The impedance measurements can be carried out at frequencies in a rangeof, for example, about 100 Hz to about 150 KHz.

Exemplary techniques for the fabrication of SiNW-ECIS and their use formonitoring the spreading stage of biological cells or therapeutic effectof anti-cancer drugs, pursuant to the teachings of the presentapplication are set forth hereinbelow. It should be understood thatthese examples are illustrative only, and similar techniques forfabrication of SiNW-ECIS and their use according to the instantapplication are thus possible with different parameters, as is all wellunderstood to those of skill in the art. The examples should not bedeemed as limiting the scope of the present application. The onlylimitations of the scope of the instant case are set forth in the claimsappended hereinbelow.

Example 1 Fabrication of SiNW-ECIS

In this example, a silicon wafer having a thickness of about 0.5 cm isused as the substrate. First, the silicon wafer was cleaned through thestandard RCA#1 cleaning method (NH₄OH: H₂O₂: H₂O solution and volumeratio of 1:1:5). Subsequently, a thin layer of SiO₂ with a thickness ofabout 300 nm was grown on the substrate by a wet oxidation furnace at atemperature of about 1050° C. Then, a 10 nm thin gold layer was coatedon the SiO₂ layer, as the catalyst layer by a sputtering system (VeecoCo.). Then, the gold layer was patterned to form a sensor region on thesubstrate. Then, the substrate with the patterned gold layer was placedin a LPCVD system (Senslran Co. Iran) and SiNWs were grown in the sensorregion by the assistance of H₂ and SiH₄ gases at a pressure of about 1mTorr and a temperature of about 450° C. to form the SiNW-ECIS. Finally,the SiNW-ECIS was transferred into a phosphorous doping furnace toenhance the conductivity of the nanowires by the diffusion ofphosphorous dopants atoms.

FIG. 6A illustrates a SEM image of the SiNWs array grown in thepatterned sensor region. For a better observation, a greatermagnification of the grown SiNWs of as-prepared SiNW-ECIS of the part601 is shown in FIG. 6B. In addition, an even more magnified SEM imageof the part 602 representing the grown SiNWs and their geometry andarchitecture are shown and FIG. 6C. It can be seen that SiNWs were grownwith a uniform size and structure in nanometer scales and are welldistributed over the patterned sensor region.

Example 2 Investigation of Biocompatibility of SiNWs

To investigate the biocompatibility of the silicon nanowires, an MTT(3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay wasapplied in this exemplary implementation of the present application. Inthe MTT assay, the viability of the cells is verified based on acolorimetric measurement as is known in the art. Initially, the surfaceof the device was sterilized using an autoclave before cell seedingprocess. Then, the QU-DB cell lines were seeded and attached on SiNWsurface according to the method described hereinabove.

FIG. 7 illustrates an SEM image of the silicon nanowires after cellsinteraction with silicon nanowires on the sensor region. The attachmentof cells 701 onto the SiNWS 702 with no need to an adhesive can beobserved from this figure in comparison with referring again to FIG. 6C,which shows the SiNWs before any interaction with cell lines.

After 24 hours, the QU-DB cell lines were removed from the substrate bytrypsin and the culture media was added to the cell solution.Subsequently, the cells were placed in the wells of a sterile 96 wellmicro plate with the same concentration and the MTT protocol was appliedon each well. In this regard, 10 μl of MTT solution with theconcentration of 5 mg/μl was added to each well. The wells wereincubated for 4 hours in a 5% CO₂ ambient at 37° C. Next, the floatmaterials were removed from the surface of the wells and 100 μl ofdimethyl sulfoxide was added to each well. After 20 min stirring of eachwell (in order to dissolving the formazane), the optical absorption ofeach well containing the cell lines was calculated in 493 nm by microplate reader system so that the percentage of viable cells versus thecontrol well can be calculated.

FIG. 8A illustrates MTT assay results of QU-DB cells seeded on SiNW-ECISwith doped and undoped silicon nanowires. This figure shows a 60%viability increase for the seeded cells on doped SiNWs and a 40%viability increase using undoped SiNWs after 24 hours, in comparisonwith a control sample. The results indicate that such nanostructuredsurface, improved the growth and proliferation of cells in respect towell plate surface.

Furthermore, the biocompatibility of SiNWs was investigated taking theflorescent images from the QU-DB cells covered on individual devicesbefore and after proliferation stages of the seeded cells (taken 6 hoursand 12 hours after the cells culturing on the surface).

The florescent images of cells are illustrated before the proliferationstages as shown in FIG. 8B and after the proliferation stages as shownin FIG. 8C. In these images, the white dots are cells which are coloredfor the florescent test. It can be observed that the number of cells wassignificantly increased after 12 hours, which shows that the cellsgrowth cycle is continued after attachment of cells onto the SiNWs.Accordingly, these images corroborate the vitality of the cells as wellas their stable biological metabolism after attachment on SiNWs.

Example 3 Monitoring the Spreading Stage of Biological Cells UsingSiNW-ECIS

In this example, initially MRC-5 was isolated form normal human lungtissue and QU-DB cell lines were isolated from malignant human lungtissue. These cells were obtained from the standard cell Banks of Iran(Pasteur Institute). The cells were cultured by maintaining in a CO₂incubator at 37° C. (5% CO₂, 95% clean air) in a RPMI-1640 medium (Sigma8758) supplemented with 5% fetalbovine serum (Gibco), and 1%penicillin/streptomycin (Gibco). The fresh medium was replaced everyday. Then, the same concentrations of MRC-5 and QU-DB cells (104#/ml)were dropped on the surface of the SiNW-ECIS device with final volume of300 μl. In one implementation, the SiNW-ECIS device is packed in aplexiglass cover sealed with biograde silicon rubber tube. Then, theSiNW-ECIS device was held in an incubator (new brunswik Co.) and theelectrical measurements were carried out after the desired period oftimes.

FIGS. 9A and 9B illustrate comparative impedance values measured forSiNW-ECIS covered by QU-DB and MRC-5 cells during different culturingstages, including 0-3.5 hours (Top-left), 3.5-6.5 hours (Top-right) and6.5-9.5 hours (Bottom) after the initial drop. It can be observed fromthese figures that the impedance has been increased during the firstinterval of culturing time (3.5 hours from initial drop) representingthe cells attachment stage for both QU-DB (FIG. 9A, Top-left) and MRC-5cells (FIG. 9B, Top-left). Accordingly, no observable difference betweenthe electrical pattern of cancerous and healthy cells is observed duringthe attachment stage. This impedance increment is due to a well demandwith dielectric properties of the cells resulted in current blocking andimpedance increase after direct attachment of the cells on nanowires.

Referring again to FIG. 9A, the top-right sided chart illustrates thespreading stage of QU-DB cells during 3 hours after the attachment ofthe malignant cells, where the impedance of the sensor is reduced incomparison with the attachment stage. In contrast, the proliferationstage (about 3 hours after spreading) of QU-DB cells had increasingeffect on the impedimetric response of SiNW-ECIS as illustrated in thebottom sided chart.

Referring again to FIG. 9B, no noticeable impedance variation wasmeasured for normal cells (MRC-5) during the second and third timeintervals (about 6 hours after the attachment phase), indicating thatthe aforesaid two stages do not affect the response of SiNW-ECIS coveredby normal or healthy cells. This is due to the fact that once the QU-DBcells enter the proliferation stages, normal cells (designated by‘MRC-5’) still stayed in spreading stage because of their so slowerproliferation rates. Thus, the impedance measurements carried out viaSiNW-ECIS device covered by normal and malignant cells would be anappropriate criterion for cancer diagnosis or cancerous state detection.

FIGS. 10A to 10G illustrate the field emission scanning electronmicroscope (FESEM) images of seeded cancer (QU-DB) and healthy normal(MRC-5) cells at different stages. It is shown in these figures thatnormal cells have slower proliferation rate and require further time forspreading and membrane extension in respect to malignant ones asdescribed hereinbelow.

FIG. 10A illustrates a FESEM image of a single QU-DB cell seeded onSiNW-ECIS at the initial drop stage, pursuant to the teachings of thepresent application.

FIG. 10B illustrates a FESEM image of a single QU-DB cell cultured onSiNW-ECIS at an attachment stage, 3.5 hours after the initial dropping.As shown, after interaction of QU-DB cells with NWs (FIG. 10A), thecells begin to attach onto nano sites of SiNW and their presence resultin current flow blocking between inter-digital transducers (IDTs) due tobeta dispersion phenomena, as shown in FIG. 9A discussed hereinabove.

FIG. 10C illustrates a FESEM image of a single QU-DB cell cultured onSiNW-ECIS at a spreading stage, 6.5 hours after the initial dropping.When the attached cancer cells are entered to spreading sequence, theirmembrane would be extended. As the membranes of malignant cells aredegraded and their dielectric parameters are disrupted during canceroustransformation, stretching of such cells reduced their membrane abilityto block the current flow. So, the impedance value of SiNW-ECISdecreased in spreading sequence of malignant cells, as shown in FIG. 9Adiscussed hereinabove.

FIG. 10D illustrates a FESEM image of a single QU-DB cell cultured onSiNW-ECIS at a proliferation or a mitosis stage, 9.5 hours after theinitial dropping. It can be seen that after 9.5 hours, the malignantcells are split and proliferated so that the electrical impedance isincreased as shown in FIG. 9A discussed hereinabove.

Referring to FIGS. 10E, 10F and 10G, FESEM images of a single MRC-5 cellcultured on SiNW-ECIS are illustrated at different time intervals frominitial dropping. These figures show the cell at attachment, spreadingand continued spreading after 3.5 hours, 6.5 hours and 9.5 hours afterthe initial dropping.

It can be observed that the attachment of the normal cells (FIG. 10E) isled to the current flow blocking similar to cancerous cells, as shown inFIG. 9A discussed hereinabove. In addition, similar extension of themembrane on nanowire occurs during the spreading sequence of normalcells (FIG. 10F), but as their membrane contains non degradedphospholipids and fatty acids their ability in current flow blocking isnot disrupted. Therefore, the current cannot penetrate toward theirextended membrane and no impedance reduction was measured in SiNW-ECIScovered by MRC-5 cells during spreading sequence (FIG. 9B). On the otherhand, the proliferation rate of a normal cell is so slower thanmalignant one; thus, the MRC-5 cells do not complete the spreading stageafter 9.5 hour as seen in FIG. 10G.

FIGS. 11A-D illustrate the impedance phase diagrams in a complementaryconfirmation with impedance value diagrams of FIG. 9. FIG. 11Aillustrates the impedance phase diagram of malignant lung cell (QU-DB)cultured on SiNW-ECIS reported from five individual tests at differentfrequencies for initial dropping (designated by the symbol ♦) and cellsattachment (designated by the symbol ▪) after 3.5 hours. FIG. 11Billustrates the impedance phase diagram of QU-DB cultured on SiNW-ECISreported from five individual tests at different frequencies for cellsattachment (designated by the symbol ▪) after 3.5 hours and spreadingstage (designated by the symbol ▴) after 6.5 hours. FIG. 11C illustratesthe impedance phase diagram of normal lung cell (MRC-5) cultured onSiNW-ECIS reported from five individual tests at different frequenciesfor initial dropping (designated by the symbol ♦) and cells attachment(designated by the symbol ▪) after 3.5 hours. FIG. 11D illustrates theimpedance phase diagram of normal lung cell (MRC-5) cultured onSiNW-ECIS reported from five individual tests at different frequenciesfor cells attachment (designated by the symbol ▪) after 3.5 hours andspreading stage (designated by the symbol ▴) after 6.5 hours.

It can be observed that the impedance phase of both QU-DB and MRC-5cells are increased (in negative values) during the attachment stagewhich are represented by FIGS. 11A and 11C. Furthermore, the phase ofQU-DB cells decreased during spreading stage (shown in FIG. 11B),meanwhile no changes in such stage for normal cells are observed in allof measured frequencies as shown in FIG. 11D.

Example 4 Detection of the Therapeutic Effect of Anti-Cancer Drugs UsingSiNW-ECIS

In this example, the diagnostic response of cells membrane to extremelylow dose of antitubulin drugs is investigated. Initially, MCF-7 celllines, isolated from grade I human breast tumors, were obtained from theNational Cell Bank of Iran (Pasteur Institute). Then, cells weremaintained in a CO₂ incubator (37° C., 5% CO₂) in RPMI-1640 mediumsupplemented with 5% fetal bovine serum, and 1% penicillin/streptomycin.The fresh medium was replaced every other day. Then, the cultured cellswere dropped on the surface of the SiNW-ECIS, designed and fabricatedpursuant to teachings of the present application. Prior to eachexperiment, cells were trypsinized to be detached from the substrate andresuspended on the SiNW surface. To minimize the effect oftrypsinization, the procedure may last for less than 4 minutes at roomtemperature of about 20° C. The samples were held in an incubator forabout 4 hours to achieve cells attachment on the SiNWs. Thereafter, theABZ drug with low concentrations of about 2.1 nano-moles per liter andthe PTX drug with low concentrations of about 0.1 nano-moles per literwere added to individual samples. Finally, the signal recording andbiological assays were investigated about 2 hours and 6 hours after thedrug treatment (6 hours and 10 hours after the beginning of culturingprocess).

Referring to FIGS. 12A-12G, comparative normalized diagrams of impedance(designated by ΔZ % and represented by solid black lines) andcapacitance changes (designated by ΔC % and represented by dashed greylines) are illustrated for MCF-7 cells seeded on SiNW electrodes aftertreating by 2.1 nano-moles per liter of ABZ and 0.1 nano-moles per literof PTX. The time interval between the drug incubation and the signalextraction are 2 hours (designated by T1) and 6 hours (designated byT2). In addition, the same diagrams are plotted for control sampleprepared with no drug treatment stage.

Referring to FIG. 12A, the comparative normalized impedance changesbetween control and ABZ (2.1 nano-moles per liter) treated MCF-7 cells 2hours after drug incubation (6 hours after dropping the cells on SiNWelectrodes) are illustrated. The evaluation of the diagram indicatesthat ABZ treating induced meanly 25% changes in the membrane impedanceof MCF-7 cells after 2 hours. Also, the comparative normalizedcapacitive plot (as a main parameter for membrane biological state)revealed that 2.1 nano-moles per liter ABZ induced 70% variations in thecapacitance of the sensor.

Referring to FIG. 12B, considerable changes in electrical parameters ofthe cells are also observed after a treatment with 0.1 nano-moles perliter of PTX. Such variations are about 50% in mean impedance of thesensor and about 60% in mean capacitance of the sensor for 2 hours aftertreatment.

According to the method described in the present example, the sampleswere maintained in an incubator so that the signal extraction wasrepeated 10 hours after cells dropping (6 hours after drug incubationfor treated samples) to monitor the time evolution of drug induced MTpolymerization/depolymerization on bioelectrical response of themembrane.

FIGS. 12C and 12D illustrate the comparative electrical responsesbetween control and drug treated samples in which the changes inelectrical impedance with respect to control sample is about 90% for ABZtreated sample and about 30% for PTX treated. The norm of capacitivechanges in control sample is about 90% more than ABZ and about and 75%more than PTX values. The comparative capacitance is in a wellcorroboration with impedance.

Referring to FIGS. 12E, 12F and 12G, the comparative responses ofcontrol sample (FIG. 12E), ABZ treated sample (FIG. 12F) and PTX treatedsample (FIG. 12G) after T1 and T2 time intervals are illustrated. It canbe observed from these figures that the effect of ABZ is sharper on thebioelectrical impedance of the membrane during time evolution. The normin impedance of the ABZ treated cells was changed about 60% for 6 hoursafter drug incubation (ABZT1 vs. ABZT2) meanwhile such variation was 15%in PTX treated cells (PTXT1 vs. PTXT2). But, time dependent variation incapacitive behavior was sharper in PTX treated sample (about 85%).

Accordingly, a mechanism for such variations in electrical impedance canbe considered to elaborate the effect of polymerization/depolymerizationprocess in the structure of MTs on bioelectrical properties of the cellmembrane whereas its reliability can be investigated by some standardtests such as Confocal, Flowcytometry and tubulin assembly assays.Therefore, a series of confocal images were taken from samples in thepresent example.

For Confocal imaging, the MCF-7 cells were grown on individual glassslides and treated with ABZ with amount of about 2.1 and 10.5 nano-molesper liter as well as PTX with amount of about 0.1 and 1 nano-moles perliter for 2 hours. In addition, an un-treated control sample wasprepared as reference for comparison. Then, samples were washed with PBSand permeabilized with microtubule stabilizing buffer [80 mM PIPES-KOH(pH 6.8), 5 mM EGTA, and 1 mM MgCl₂ containing 0.5% Triton X-100] for 5min at room temperature before being fixed with chilled absolutemethanol for 10 min at −20° C. Thereafter, the fixed cells were washedand incubated with monoclonal mouse anti-α-tubulin antibody (Sigma Co.)for 1 hour at room temperature followed by incubation withFITC-conjugated antimouse IgG antibody (Santa Cruz Biotechnology). Thestained cells were mounted with Vectashield (Vector Laboratories,Burlingame, Calif.) and observed by confocal microscopy.

Referring to FIGS. 13A, 13B and 13C, the confocal microscopy images fromthe tubulin assemblies of MCF-7 cells 2 hours after treatment areillustrated respectively for control (un-treated) sample, treated samplewith 2.1 nano-moles per liter ABZ and treated sample with 0.1 nano-molesper liter PTX.

Referring to FIG. 13A, the confocal image taken from untreated cellsrevealed that normal bipolar spindles are observed in cytoskeletalstructure. In contrast, many cells having abnormally reduced numbers ofspindles or monopolar (monoaster) spindles for ABZ treated sample asillustrated in FIG. 13B. In contrast, aggregated spindles are observedfor PTX treated cells after the same time referring to FIG. 13C.

The confocal microscopy images from the tubulin assemblies of MCF-7cells 6 hours after treatment are illustrated for control sample (FIG.14A), treated sample with 2.1 nano-moles per liter ABZ (FIG. 14B) andtreated sample with 0.1 nano-moles per liter PTX (FIG. 14C).

Referring to FIG. 14B, the spindle inhibitory effects of ABZ iscontinuously observable 6 hours after drug treatment and still themonoastered MTs are observable in comparison with control sample shownin FIG. 14A. In addition, the increased aggregation in MT spindles isnoticeable in PTX treated sample after 6 hours, referring to FIG. 14C.

Hence, the confocal images precisely corroborate the interference of ABZand PTX on MT assembly in which the perturbation indepolymerization/polymerization rate of MTs affect the normal functionof membrane and change the electrical characteristics of thephospholipids and ion channels. ABZ analogues is one class of inhibitorsthat operates by depolymerization of tubulin to form microtubules and socalled polymerization inhibitor. It reduces the mass of microbulepolymer in the cells and acts as a microtubule-destabilizing agent(FIGS. 13B and 14B). PTX analogues which is the other class ofinhibitors operates by inhibiting the depolymerization of polymerizedtubulin and enhances the mass of microtubule polymer in the cells.Therefore, it acts as microbule-stabilizing agent calleddepolymerization inhibitor (FIGS. 13C and 14C).

Other implementations are contemplated. For example, electrically activenanostructures, such as carbon nanotube, silicon nanowires andnanograsses may be suitable candidates for a well-directed electricalinteraction with cell outer-wall to penetrate the electric field intothe cell inner parts. Among these, the most important advantage ofSiNW-ECIS in addition to the silicon nanowires biocompatibility withbiological cells is the direct attachment of biological cells without aneed for adhesive layers.

The elasticity and skein architecture of nanowires permit the cells tospread and proliferate on the wires. As can be observed from SEM images,the cells are formed in a 3D shape during proliferation on SiNW arrays.This important ability may allow for great electrical monitoring ofcells by 3D electrically activated SiNW electrodes during their growthand mitosis. Additionally, SiNWs could be grown on top of SiO₂ layer andthen be doped in a doping furnace. Therefore, a good electricalisolation may be achieved between electrodes and substrate.

As such, SiNWs may be more advantages than other electrically activenanostructures. For example, in the case of Si nanograsses, Sinanograsses may have to be fabricated onto the Si substrate by reactiveion etching. Therefore, isolating the electrodes from each other may becomplicated and may require multi-step sequential p and n doping to forma reverse bias between the electrodes and substrate. It should beunderstood by a person skilled in the art that the passivizing qualityof the oxide layer is much better than a reverse junction.

While the foregoing has described what are considered to be the bestmode and/or other examples, it is understood that various modificationsmay be made therein and that the subject matter disclosed herein may beimplemented in various forms and examples, and that the teachings may beapplied in numerous applications, only some of which have been describedherein. It is intended by the following claims to claim any and allapplications, modifications and variations that fall within the truescope of the present teachings.

Unless otherwise stated, all measurements, values, ratings, positions,magnitudes, sizes, and other specifications that are set forth in thisspecification, including in the claims that follow, are approximate, notexact. They are intended to have a reasonable range that is consistentwith the functions to which they relate and with what is customary inthe art to which they pertain.

The scope of protection is limited solely by the claims that now follow.That scope is intended and should be interpreted to be as broad as isconsistent with the ordinary meaning of the language that is used in theclaims when interpreted in light of this specification and theprosecution history that follows and to encompass all structural andfunctional equivalents. Notwithstanding, none of the claims are intendedto embrace subject matter that fails to satisfy the requirement ofSections 101, 102, or 103 of the Patent Act, nor should they beinterpreted in such a way. Any unintended embracement of such subjectmatter is hereby disclaimed.

Except as stated immediately above, nothing that has been stated orillustrated is intended or should be interpreted to cause a dedicationof any component, step, feature, object, benefit, advantage, orequivalent to the public, regardless of whether it is or is not recitedin the claims.

It will be understood that the terms and expressions used herein havethe ordinary meaning as is accorded to such terms and expressions withrespect to their corresponding respective areas of inquiry and studyexcept where specific meanings have otherwise been set forth herein.Relational terms such as first and second and the like may be usedsolely to distinguish one entity or action from another withoutnecessarily requiring or implying any actual such relationship or orderbetween such entities or actions. The terms “comprises,” “comprising,”or any other variation thereof, are intended to cover a non-exclusiveinclusion, such that a process, method, article, or apparatus thatcomprises a list of elements does not include only those elements butmay include other elements not expressly listed or inherent to suchprocess, method, article, or apparatus. An element proceeded by “a” or“an” does not, without further constraints, preclude the existence ofadditional identical elements in the process, method, article, orapparatus that comprises the element.

The Abstract of the Disclosure is provided to allow the reader toquickly ascertain the nature of the technical disclosure. It issubmitted with the understanding that it will not be used to interpretor limit the scope or meaning of the claims. In addition, in theforegoing Detailed Description, it can be seen that various features aregrouped together in various examples for the purpose of streamlining thedisclosure. This method of disclosure is not to be interpreted asreflecting an intention that the claims require more features than areexpressly recited in each claim. Rather, as the following claimsreflect, inventive subject matter lies in less than all features of asingle disclosed example. Thus the following claims are herebyincorporated into the Detailed Description, with each claim standing onits own as a separately claimed subject matter.

What is claimed is:
 1. A method for detection and monitoring atherapeutic effect of a cancer treatment drug, the method comprisingsteps of: removing a malignant biological cell lines from a tumor;culturing the removed biological cell lines in a controlled set ofconditions; seeding the cultured biological cell lines on siliconnanowire electrode arrays of an electrical cell-substrate impedancesensor (ECIS); adding a cancer treatment drug to the seeded biologicalcell lines to treat the seeded biological cell lines; and measuring anelectrical impedance of the treated biological cell lines for detectionand monitoring a therapeutic effect of the cancer treatment drug.
 2. Themethod according to claim 1, wherein the tumor includes a malignantcancerous tumor.
 3. The method according to claim 1, wherein the tumorincludes a breast tumor.
 4. The method according to claim 1, wherein themalignant biological cell lines include MCF-7 (Michigan CancerFoundation-7) cell lines isolated from a grade I human breast tumor. 5.The method according to claim 1, wherein the controlled set ofconditions includes maintaining the cell lines in a CO₂ incubator. 6.The method according to claim 5, wherein the CO₂ incubator includes acomposition of CO₂ and clean air.
 7. The method according to claim 6,wherein the CO₂ has a percentage of about 5% and the clean air has apercentage of about 95%.
 8. The method according to claim 1, wherein thecontrolled set of conditions includes maintaining the removed biologicalcell lines at a temperature of about 37° C.
 9. The method according toclaim 1, wherein the controlled set of conditions includes maintainingthe removed biological cell lines in a Roswell Park MemorialInstitute-1640 (RPMI-1640) medium.
 10. The method according to claim 9,wherein the medium is supplemented with a Fetalbovine serum comprisingof Fetalbovine with an amount of about 5%.
 11. The method according toclaim 9, wherein the medium is supplemented with penicillin/streptomycinwith an amount of about 1%.
 12. The method according to claim 9, whereinthe medium is replaced every day with a fresh medium.
 13. The methodaccording to claim 1, wherein the ECIS is packed in a plexiglass cover.14. The method according to claim 1, wherein the ECIS is sealed with abiograde silicon rubber tube.
 15. The method according to claim 1,wherein seeding the cultured biological cell lines includes: droppingthe cultured biological cell lines on a surface of a packed and sealedECIS, and maintaining the dropped biological cell lines in an incubatorto achieve attachment between the biological cell lines and the siliconnanowire electrode arrays of ECIS.
 16. The method according to claim 15,wherein the dropped biological cell lines are trypsinized for less than4 minutes and at room temperature of about 20° C. to detach from thesubstrate and re-suspend on the silicon nanowire electrode arrays. 17.The method according to claim 15, wherein dropping the culturedbiological cell lines includes dropping the cultured biological celllines with a volume of about 300 μl.
 18. The method according to claim15, wherein maintaining the cultured biological cell lines in theincubator includes maintaining the cultured biological cell lines in theincubator for about 3 hours to 10 hours.
 19. The method according toclaim 1, wherein adding the treatment drug includes: adding a specificamount of the treatment drug on a surface of the biological cell linesattached on the silicon nanowire electrode arrays, and maintaining thebiological cell lines with the added treatment drug in an incubator fora specific time interval.
 20. The method according to claim 19, whereinthe treatment drug is an antitubulin drug selected from a groupconsisting of Albendazole (ABZ), Paclitaxel (PTX) or any otherantitubulin drug.
 21. The method according to claim 20, wherein the ABZdrug has a concentration in a range of about 0.1 to 20 nano-mole perliter.
 22. The method according to claim 20, wherein the PTX drug has aconcentration in a range of about 0.1 to 20 nano-mole per liter.
 23. Themethod according to claim 19, wherein maintaining the biological celllines with the added treatment drug includes maintaining the biologicalcell lines with the added treatment drug in the incubator for at leastabout 2 hours.
 24. The method according to claim 1, wherein: measuringthe electrical impedance includes measuring the electrical impedance viaa device having a sensor package; a system configured to apply anelectrical signal to the sensor package and to acquire an electricalresponse corresponding to the electrical signal from the sensor package;and a data processor configured to process the electrical response, andthe ECIS includes a substrate, a catalyst layer formed on the substrate,and the silicon nanowire electrode arrays grown on the catalyst layer.25. The method according to claim 24, wherein measuring the electricalimpedance includes: applying a specific voltage to the sensor packagehaving the biological cells attached to the silicon nanowire electrodearrays, and measuring the electrical impedance of the biological cellsattached to the silicon nanowire electrode arrays at various specificfrequencies.
 26. The method according to claim 25, wherein measuring theelectrical impedance is performed about 2 hours and 6 hours after thedrug treatment.
 27. The method according to claim 25, wherein theapplied voltage is about 400 mV.
 28. The method according to claim 25,wherein the measurement is carried out at a range of frequencies fromabout 100 Hz to 150 KHz.